Literature DB >> 1719024

Glycoinositol phospholipids from American Leishmania and Trypanosoma spp: partial characterization of the glycan cores and the human humoral immune response to them.

J L Avila1, M Rojas, A Acosta.   

Abstract

The glycoinositol phospholipid (GIPL) profiles of American Leishmania spp. (L. mexicana and L. braziliensis), Leishmania donovani, and American Trypanosoma spp. (T. cruzi and T. rangeli) were compared. The major GIPLs in these parasites include tetraglycosyl-, pentaglycosyl-, and hexaglycosylphosphatidylinositol. These were partially identified by their comigration by high-performance thin-layer chromatography with purified L. major GIPLs, gas-liquid chromatography of the monosaccharides released after aqueous HF treatment, N-acetylation and methanolysis, sensitivity to exoglycosidases, and antibody absorption on several specific natural haptens. Members of the genus Leishmania have two other highly polar glycolipids, while the T. rangeli glycolipid profile was quite different from those of other kinetoplastids that were studied. On a weight basis, the glycan core of L. major GIPL-1 is the most reactive, followed by GIPL-3 and GIPL-2. Antibodies to the core glycans of GIPL-1, GIPL-2, and GIPL-3 were present at a low titer in the serum of every normal individual studied, while elevated GIPL-2 antibody levels were present in 80 to 100% of T. cruzi-, T. rangeli-, or L. donovani-infected patients, with lower values being found for GIPL-3 (30 to 60%) and GIPL-1 (30 to 50%). Except for GIPL-2 antibodies, which were mainly located on immunoglobulin G (IgG) and IgM, GIPL-1 and GIPL-3 antibodies were mainly distributed in IgM, with lower reactivity present in IgG. Antigen-antibody binding was very selectively blocked with Gal(alpha 1-3)Man, or Gal(beta 1-4)Man, Gal(alpha 1-3)Gal, and Gal(alpha 1-6)Gal for GIPL-1, GIPL-2, and GIPL-3 antibodies, respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719024      PMCID: PMC270318          DOI: 10.1128/jcm.29.10.2305-2312.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  A hydrolytic procedure for the identification and estimation of individual phospholipids in biological samples.

Authors:  R M DAWSON
Journal:  Biochem J       Date:  1960-04       Impact factor: 3.857

2.  Antibodies to laminin in Trypanosoma rangeli-infected subjects.

Authors:  J L Avila; M Rojas; G Velazquez-Avila; M Rieber
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

Review 3.  Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures.

Authors:  M A Ferguson; A F Williams
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

4.  Serological activity against galactosyl-alpha(1-3)galactose in sera from patients with several kinetoplastida infections.

Authors:  J L Avila; M Rojas; H Towbin
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

5.  Persistence of elevated levels of galactosyl-alpha(1-3)galactose antibodies in sera from patients cured of visceral leishmaniasis.

Authors:  J L Avila; M Rojas; L García
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

6.  Trypanosoma cruzi: defined medium for continuous cultivation of virulent parasites.

Authors:  J L Avila; A Bretaña; M A Casanova; A Avila; F Rodríguez
Journal:  Exp Parasitol       Date:  1979-08       Impact factor: 2.011

7.  Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.

Authors:  J Convit; P L Castellanos; A Rondon; M E Pinardi; M Ulrich; M Castes; B Bloom; L Garcia
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

Review 8.  Anti-alpha-galactosyl antibodies in chagasic patients. Possible biological significance.

Authors:  S R Milani; L R Travassos
Journal:  Braz J Med Biol Res       Date:  1988       Impact factor: 2.590

9.  Defective transport of pyrazolopyrimidine ribosides in insensitive Trypanosoma cruzi wild strains is a parasite-stage specific and reversible characteristic.

Authors:  J L Avila; A Avila
Journal:  Comp Biochem Physiol B       Date:  1987

10.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora.

Authors:  U Galili; R E Mandrell; R M Hamadeh; S B Shohet; J M Griffiss
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

View more
  10 in total

Review 1.  Carbohydrate immunity in American trypanosomiasis.

Authors:  L R Travassos; I C Almeida
Journal:  Springer Semin Immunopathol       Date:  1993

Review 2.  The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes.

Authors:  M J McConville; M A Ferguson
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

3.  Reversed Immunoglycomics Identifies α-Galactosyl-Bearing Glycotopes Specific for Leishmania major Infection.

Authors:  Alba L Montoya; Victoria M Austin; Susana Portillo; Irodiel Vinales; Roger A Ashmus; Igor Estevao; Sohan R Jankuru; Yasser Alraey; Waleed S Al-Salem; Álvaro Acosta-Serrano; Igor C Almeida; Katja Michael
Journal:  JACS Au       Date:  2021-07-12

4.  The efficacy of L. (L.) chagasi excreted-secreted antigens (ESAs) for visceral leishmaniasis diagnosis is due to low levels of cross-reactivity.

Authors:  Viviana Pinedo-Cancino; Norival Kesper; Clara Lúcia Barbiéri; José Angelo Lauletta Lindoso; Eufrosina Setsu Umezawa
Journal:  Am J Trop Med Hyg       Date:  2013-01-16       Impact factor: 2.345

5.  Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi.

Authors:  I C Almeida; M A Ferguson; S Schenkman; L R Travassos
Journal:  Biochem J       Date:  1994-12-15       Impact factor: 3.857

6.  Characterization of glycoinositol phospholipids in the amastigote stage of the protozoan parasite Leishmania major.

Authors:  P Schneider; J P Rosat; A Ransijn; M A Ferguson; M J McConville
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

7.  An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

Authors:  Eva Iniguez; Nathaniel S Schocker; Krishanthi Subramaniam; Susana Portillo; Alba L Montoya; Waleed S Al-Salem; Caresse L Torres; Felipe Rodriguez; Otacilio C Moreira; Alvaro Acosta-Serrano; Katja Michael; Igor C Almeida; Rosa A Maldonado
Journal:  PLoS Negl Trop Dis       Date:  2017-10-25

8.  Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins.

Authors:  Sayonara M Viana; Alba L Montoya; Augusto M Carvalho; Brunele S de Mendonça; Susana Portillo; Janet J Olivas; Nasim H Karimi; Igor L Estevao; Uriel Ortega-Rodriguez; Edgar M Carvalho; Walderez O Dutra; Rosa A Maldonaldo; Katja Michael; Camila I de Oliveira; Igor C Almeida
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

9.  Leishmania mexicana infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans.

Authors:  Laurence U Buxbaum
Journal:  PLoS Negl Trop Dis       Date:  2013-05-09

10.  α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model.

Authors:  Gisele Macêdo Rodrigues da Cunha; Maíra Araújo Azevedo; Denise Silva Nogueira; Marianna de Carvalho Clímaco; Edward Valencia Ayala; Juan Atilio Jimenez Chunga; Raul Jesus Ynocente La Valle; Lucia Maria da Cunha Galvão; Egler Chiari; Carlos Ramon Nascimento Brito; Rodrigo Pedro Soares; Paula Monalisa Nogueira; Ricardo Toshio Fujiwara; Ricardo Gazzinelli; Robert Hincapie; Carlos-Sanhueza Chaves; Fabricio Marcus Silva Oliveira; M G Finn; Alexandre Ferreira Marques
Journal:  PLoS Negl Trop Dis       Date:  2021-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.